

Product Data Sheet

Cas No.:	256498-66-5	Cat. No:	PC15329
Product Name:		BAY 41-8543	
Product synonym:	2-[1-[(2-氟苯基)甲基]-1H-吡	k唑并[3,4-B]吡啶-3-基]-5-(4-吗啉基)-4,6-	嘧啶二胺;化合物BAY 41-8543
Chemical name:		BAY 41-8543	
MF:	C21H21N8OF	FW:	420.443
Purity:	≥98%	Batch No.:	-
Storage:			
Structural formula:		H 2 N N H 2 N N H 2 N N N N N N N N N N	
λmax:	-	Formulation:	-
Solubility :			
SMILES:	FC1=C(C=CC=C	1)CN2N=C(C3=CC=CN=C32)C4=NC(N)=C(C(N)=N4)N5CCOCC5
InChI Code:		-	
InChl Key:			
	WARNING TI.	is not for human or veterinary use.	

Product Description

可溶性鸟苷酸环化酶(sGC)的血红素依赖性刺激剂,BAY 41-8543 is an NO-independent sGC (soluble guanylyl cyclase) stimulator, inhibits collagenmediated aggregation in washed human platelets (IC50=90 nM).

生物活性 vasodilator activity in the pulmonary and systemic vascular beds in the rat. BAY 41-8543 has antiplatelet effects and has the potential for cardiovascular diseases research.
--

BAY 41-8543 (10-100 μg/kg; IV) produces small decreases in pulmonary arterial pressure, larger dose-dependent decreases in systemic arterial pressure, and increases in cardiac output. BAY 41-8543 (0.003, 0.01, 0.03, 0.1, and 0.3?mg/kg; iv) produces a dose-dependent and long-lasting decrease in blood pressure in anaesthetized rats. The blood pressure lowering effect of BAY 41-8543 lasts longer than the observation period of 30?min. BAY 41-8543 (0.1, 0.3 and 1.0?mg?kg; oral) has maximal blood pressure lowering effects. The blood pressure lowering effects of the highest doses of BAY41-8543 lasts longer than the observation period of 120?min. BAY 41-8543 (3?mg/kg; p.o.; twice daily; for 5 weeks) completely prevents the development of the increase in systolic blood pressure in 18-week-old renin transgenic rats (TGR(mRen2)27) on L-NAME treatment. BAY 41-8543 dramatically increases 体内研究(In Vivo) survival. Medlife has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Adult male Sprague-Dawley rats weighing 325-450 g 10, 30, and 100 μg/kg Dosage: Administration: IV Result: Produced small decreases in pulmonary arterial pressure, larger dose-dependent decreases in systemic arterial -20°C Powder 3 years 4°C 2 years 包装储存 In solvent -80°C 6 months -20°C 1 month 体外研究: DMF: 16.67 mg/mL (39.65 mM; Need ultrasonic) Ethanol: 1 mg/mL (2.38 mM; ultrasonic and warming and heat to 70°C) DMSO: < 1 mg/mL (ultrasonic; warming; heat to 60°C) (insoluble or slightly soluble) 质量 溶剂体积 1 mg 5 mg 10 mg 浓度

溶解度数据

溶剂体积 浓度 1 mg 5 mg 10 mg 配制储备溶液 1 mM 2.3785 mL 11.8923 mL 23.7846 mL 5 mM 0.4757 mL 2.3785 mL 4.7569 mL 10 mM 0.2378 mL 1.1892 mL 2.3785 mL

* 产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,**建议分装保存,避免反复** 冻融造成的产品失效。

储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。-80°C 储存时,建议在 6 个月内使用,-20°C 储存时,建议在 1 个月内使用。